Research progress of 68Ga-PSMA PET/CT in the diagnosis of prostate cancer
10.3760/cma.j.issn.2095-2848.2019.04.012
- VernacularTitle:68Ga-PSMA PET/CT在前列腺癌诊断中的研究进展
- Author:
Yaqi FENG
1
;
Bangping CUI
;
Peng WANG
;
Wenli DAI
;
Pengyi DENG
;
Jinling TIAN
Author Information
1. 三峡大学第一临床医学院、宜昌市中心人民医院核医学科、宜昌市核医学分子影像重点实验室 443003
- Keywords:
Prostatic neoplasms;
Prostate-specific membrane antigen;
Isotope labeling;
Gallium radioisotopes;
Positron-emission tomography;
Tomography,X-ray computed;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2019;39(4):237-240
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of prostate cancer has shown an obvious upward trend in recent years.18F-fluorodeoxyglucose(FDG)is a broad-spectrum imaging agent for cancer,but there is a " blind zone" in the application of prostate cancer.Therefore,exploring prostate imaging agents with better performance can help to make up the deficiency.At present,there are a number of positron imaging agents for prostate cancer,but the overall advantage is not obvious.Recently,a new imaging agent,68Ga-prostate specific membrane antigen(PSMA),has been demonstrated its better value in clinical application of prostate cancer.This review summarizes the research progress of 68 Ga-PSMA,
